324 results about "Prostatic Cancers" patented technology

The invention provides a multi-mode prostate cancer biochemical recurrence risk layering prediction system based on artificial intelligence. Based on an Xgboost framework, a postoperative patient pathological panoramic pathological section scanning image is analyzed through end-to-end, multi-scale, multi-center and large-sample analysis, pathological information is utilized to the maximum extent, meanwhile, the prognosis risk of a patient can be evaluated more comprehensively in combination with clinical indexes such as CAPRA-S scores, and the method has obvious advantages compared with a traditional model. The method aims at better fitting the use scene of a hospital, the risk of prostate cancer recurrence of a patient is more efficiently and accurately predicted by fusing pathological section features and clinical features after a radical operation, and the risk of recurrence of the patient within 3 years and longer time after the radical operation can be accurately predicted. And an interpretable module is further combined to assist a doctor to interpret a result, so that precise layering and personalized follow-up visit of the BCR risk of the prostatic cancer patient are realized, the risk of excessive treatment and missed diagnosis is reduced, and the method has a good application prospect.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention provides a prostate cancer biochemical recurrence prediction system based on a deep learning image and clinical information multi-mode model. The prostate cancer biochemical recurrence prediction system comprises an input module, a preprocessing module, a feature selection module, a fusion module, a prediction module, a data management and storage module and a result output and decision support module. According to the method, bpMRI image data and clinical information of a patient are fully utilized, multi-mode information is fully fused through a deep learning technology, and accurate prediction of biochemical recurrence is achieved. And the robustness of the model is further enhanced by adopting 5-fold cross validation and a diversified data enhancement strategy. Experimental results show that the method can assist in making more accurate patient layering and personalized follow-up visit schemes, and potentially reduces the over-treatment and missed diagnosis risks. The invention provides an efficient and reliable AI solution for prostatic cancer prognosis evaluation, and provides powerful support for promoting precise medical treatment and making personalized treatment strategies.

The embodiment of the invention provides a Grignson grading method and device for a prostate cancer pathological image, equipment and a medium. The method comprises the following steps: acquiring a prostate cancer pathological image which is a full-view digital slice image; dividing a non-blank area of the prostatic cancer pathological image into a plurality of non-overlapping examples; converting the instance into a high-dimensional feature vector; the high-dimensional feature vector is input to a pre-trained multi-branch hybrid supervised network model, slice-level representation is obtained, the multi-branch hybrid supervised network model comprises an attention backbone network, instance-level branches and slice-level branches, the slice-level branches comprise slice-level benign branches and slice-level malignant branches, and slice-level representation is obtained; the slice-level malignant branch comprises an instance compression module and a component extraction module; and inputting the slice level representation into a classifier to obtain a Grignson classification result of the prostatic cancer pathological image. Based on this, the embodiment of the invention can improve the accuracy of Gleason grading of the prostatic cancer pathological image.

The invention belongs to the field of characterization learning, and particularly relates to a prostate cancer diagnosis method based on a multimodal large model prompt learning mechanism. Comprising the following steps: step 1, data preprocessing; 2, key frames and similarity are calculated, and irrelevant editing is compressed; step 3, text and image alignment training; step 4, a test stage; according to the method, a similarity-based screening mechanism is provided, ultrasonic videos under coarse-grained labels are preliminarily screened under segmentation of a large model, and focus areas are focused on in time sequence; meanwhile, a pre-processing mechanism based on a large model is provided, and the influence of a large amount of irrelevant information existing in prostate ultrasonic image scanning on the model is compressed at a data end, so that the diagnosis effect of the model is improved.

The invention provides a prostate cancer focus accurate positioning method based on a fusion navigation technology, and relates to the technical field of data processing, and the method comprises the steps: collecting a plurality of prostate images; selecting a control point from the prostate image in combination with a sparse regularization algorithm; determining an optimal deformation field according to the control points, and performing elastic registration on the prostate image based on the optimal deformation field; differential multi-resolution fusion is carried out on the registered prostate images, and a prostate three-dimensional model is reconstructed; constructing a lesion dynamic extraction model comprising a three-dimensional convolutional network, a pooling layer, an interested layer and a bounding box regression layer which are connected in sequence; a loss function of the focus dynamic extraction model is established, and the loss function comprises an intersection-to-union ratio loss item and a distributed focus loss item; under the supervision of the loss function, training the focus dynamic extraction model; and positioning a lesion point in the prostate three-dimensional model through the trained lesion dynamic extraction model. And the focus point positioning speed and accuracy are improved.

A real-time artificial intelligence (AI) framework is provided for the automated analysis of radiological images and detection of disease, such as extracapsular extension (ECE) in prostate cancer. The system includes a dual deep learning architecture comprising a first convolutional neural network (CNN) for identifying diagnostically relevant image slices from three-dimensional MRI data, and a second CNN for classifying disease presence based on those slices. A preprocessing pipeline standardizes and harmonizes image input, and cropping algorithms isolate the region of interest for enhanced model performance. This framework enables scalable, high-accuracy diagnosis across various imaging modalities including but not limited to MRI, CT, PET, ultrasound, and diverse disease types, improving clinical decision-making and supporting integration into real-time radiology workflows.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.

The invention discloses a prostate PSMA PET / CT and enhanced MR multi-modal image registration and fusion method based on deep learning. The method comprises the following steps: preprocessing acquired PSMA PET / CT and enhanced MRI data; a multi-scale multi-stage registration network comprising the semantic gating convolution module and a U-CLSTM module is constructed: the SGC module enhances global perception ability through a V channel, the U-CLSTM module reinforces local feature attention by using a U channel, deformation field iterative optimization is performed in combination with a pyramid structure, and a multi-scale multi-stage registration network comprising the semantic gating convolution module and the U-CLSTM module is constructed; and finally, generating a high-precision registration image through Y channel weighted fusion. According to the method, global information self-adaption and local feature enhancement are combined, the registration precision of a gland anatomical structure and a tumor focus is synchronously improved through a multi-scale pyramid structure, PSMAPT / CT functional metabolism information and MRI anatomical structure information are effectively integrated, the generated three-dimensional fusion image can visually display the spatial position, morphological features and invasion range of a tumor, and the accuracy of the three-dimensional fusion image is improved. A multi-modal image basis with high space consistency is provided for clinical diagnosis, and the diagnosis accuracy of the prostate cancer is remarkably improved.

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.

The invention discloses a new application of human YTHDF1, namely an application of a human YTHDF1 gene expression quantity detection reagent in preparation of a prostatic cancer clinical diagnosis reagent. The expression of the human YTHDF1 gene in prostatic cancer tissues and cell lines is increased; after the expression of the YTHDF1 gene is knocked down, the growth of a prostate cancer cell line, the culture of organoids and the growth of transplanted tumors in nude mice are obviously inhibited; according to the present invention, with the application of the RNF7 in the tumor cells, the proliferation of the normal prostate epithelial cells can be promoted by the overexpression, the protein level of the RNF7 in the YTHDF1 knocked-down cells is significantly inhibited, the phenotype of the YTHDF1 knocked-down cells can be rescued by the overexpression of the RNF7, and the sensitivity of the tumor cells to the chemotherapeutic drugs can be promoted by the YTHDF1 knocked-down cells so as to promote the apoptosis; the prostatic cancer can be treated by inhibiting expression drugs of the human YTHDF1 gene, inhibiting expression of the E3 ubiquitin ligase RNF7 gene or screening drugs for degrading the E3 ubiquitin ligase RNF7.

The invention belongs to the technical field of in-vitro diagnostic reagents, and particularly relates to application of a detection reagent for GDF15 protein in extracellular vesicles in preparation of a prostate cancer diagnosis and / or staging kit. According to the invention, enrichment and proteomics detection are carried out on plasma EVs of patients with prostatic cancer (PCa) and benign prostatic hyperplasia (BPH), and through bioinformatics analysis, a potential EV protein marker GDF15 which can be used for early diagnosis of PCa is screened for the first time. The GDF15 protein is verified in a plurality of groups of new clinical queues by further adopting an immunological technology and a targeted quantitative mass spectrometry technology, and the distinguishing ability of the GDF15 protein to PCa and BPH and the distinguishing ability of the GDF15 protein to different PCa stages are determined. The method is expected to promote noninvasive precise diagnosis of clinical PCa, and has a good application prospect.

The invention relates to the technical field of artificial intelligence, and discloses a prostate cancer early screening model construction method based on deep learning. The method comprises the following steps: acquiring a multi-modal magnetic resonance imaging data set; segmenting the positive focus and encoding the positive focus into pathological state vectors; constructing a conditional generative adversarial network under pathological state constraints to generate a synthetic focus image with specified pathological features; seamlessly embedding the synthetic focus into a healthy background through a gradient domain fusion algorithm to generate a high-reality positive sample; and integrating the original and synthetic samples to train a three-dimensional convolutional neural network screening model. The system comprises a multi-modal image acquisition module, a pathological feature vectorization module, a condition generation module, a focus fusion module and a model training deployment module. According to the method, the model generalization ability and the early screening accuracy are remarkably improved, and the missed diagnosis rate is effectively reduced.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention discloses application of a small molecular compound secalonic acid B in inhibiting Skp2 protein and resisting prostate cancer cell metastasis, and belongs to the technical field of medicines. The research finds that secalonic acid B can obviously reduce the half-life period of Skp2, accelerate the degradation speed of Skp2 and reduce the protein level of Skp2 in DU145 cells by enhancing the polyubiquitination process on Skp2 protein. The secalonic acid B induces proteasome degradation of Skp2 through a multi-ubiquitination pathway of a K48 chain, so that tumor cell metastasis is inhibited, and the effect of resisting prostatic cancer is achieved. The invention discloses an action mechanism of secalonic acid B in inhibiting Skp2 protein and resisting prostate cancer cell metastasis, lays a theoretical foundation for research and development of drugs for inhibiting Skp2 protein and treating prostate cancer, and provides a new strategy for treatment of prostate cancer.

The present invention belongs to the field of biomedicine, and particularly relates to an lncRNA ENST00000510619 for the treatment of prostate cancer and its application. The cDNA sequence of lncRNA ENST00000510619 is shown as SEQ ID NO.1. The present invention discovers that the expression of lncRNA ENST00000510619 in mCRPC and mHSPC prostate cancer tissues is significantly higher than that in normal prostate tissues, and the expression of lncRNA ENST00000510619 in mCRPC prostate cancer tissues is significantly higher than that in mHSPC prostate cancer tissues; inhibiting / knocking out lncRNA ENST00000510619 can inhibit the proliferation, migration and invasion of prostate cancer cells, and enhance the sensitivity of docetaxel-induced apoptosis of prostate cancer cells. Therefore, lncRNA ENST00000510619 can be used as a therapeutic target for prostate cancer.

The present invention relates to a sustained-release injectable composition containing dutasteride. Compared with the conventional Avodart (registered trademark) taken once a day, even if the dosage of dutasteride is the same as or less than that of Avodart, it is possible to show a sustained release effect of dutasteride for 3 months or more, and a long-term drug-taking effect can be shown by a single injection. In addition, it can show a therapeutic effect on benign prostatic hyperplasia, prostate cancer, and hair loss continuously for 3 months or more. The microparticles contained in the sustained-release injectable composition have a constant average diameter, can regulate the release of the drug, and maintain a constant effective drug concentration, and can reduce the foreign body sensation and pain when administered to patients as an injection.

The present invention relates to crystalline particles of N-((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazol-3-carboxamide (I) having a specific surface area (SSA) in the range of from about 8 to about 16 m2 / g, preferably from about 10 to about 15 m2 / g, and to a process for preparing said particles. Compound (I) is potent androgen receptor (AR) modulators, which are useful as medicaments, for example in the treatment of prostate cancer.

The present application relates to the technical field of medical imaging processing, in particular to a puncture planning method and system based on prostate multi-modal imaging and a storage medium, comprising: planning a first path with a prostate cancer region as a target point in prostate multi-modal imaging; acquiring an ultrasound image of a puncture needle in a running process according to the first path in real time; detecting and segmenting the puncture needle in the ultrasound image and determining positioning information of a needle tip of the puncture needle; registering the first path to the ultrasound image in the prostate multi-modal imaging and determining correction information of the puncture needle running process by using the first path and the positioning information of the needle tip of the puncture needle. The present application plans a puncture path of prostate cancer on prostate multi-modal imaging, realizes providing guiding information for puncture, and accurately positions a puncture needle shape and positioning information in a puncture guiding process through ultrasound guiding, so as to accurately guide or correct information in a puncture process by using a planned path.

The invention discloses 5 alpha-reductase degradation molecules as well as a preparation method and application thereof, four 5 alpha-reductase degradation molecules can realize thorough removal of zymoprotein by inducing proteasome-dependent degradation of 5 alpha-reductase instead of only inhibiting the activity of the 5 alpha-reductase, so that a more lasting treatment effect is obtained; under the condition of equal dosage, the effect of the 5 alpha-reductase degradation molecule on treating the benign prostatic hyperplasia is superior to that of the traditional inhibitor finasteride; the four kinds of 5 alpha-reductase degrading molecules can effectively degrade 5 alpha-reductase protein and remarkably inhibit development of benign prostatic hyperplasia, have good biological safety and provide new strategies and candidate drugs for treatment of diseases related to 5 alpha-reductase such as benign prostatic hyperplasia, prostatic cancer, androgenetic alopecia and acne.

The present invention belongs to the field of biomedicine technology, and relates to the application of the Lnc-FLJ gene in the treatment of castration-resistant prostate cancer. The application of the Lnc-FLJ gene inhibitor in the preparation of prostate cancer drugs. The present invention discovered for the first time that Lnc-FLJ can inhibit the proliferation and autophagy of castration-resistant prostate cancer. Lnc-FLJ is more highly expressed in castration-resistant prostate cancer cells and prostate cancer tissues with higher malignancy. Inhibiting Lnc-FLJ can inhibit the occurrence and development of castration-resistant prostate cancer. The preparation of Lnc-FLJ small molecule inhibitor shRNA is used to treat castration-resistant prostate cancer and cancer insensitive to enzalutamide, thereby inhibiting the AR signaling pathway. The present invention provides new ideas for further studying the pathogenesis of castration-resistant prostate cancer and the function of the Lnc-FLJ gene, and provides a new direction for the development of castration-resistant prostate cancer drugs.

The invention discloses a double-target chimeric antigen receptor capable of simultaneously targeting TLL1 and B7H3, a CAR-T cell and application of the double-target chimeric antigen receptor. The chimeric antigen receptor is a fusion protein which is sequentially composed of Omburt-scFv (SEQ ID NO: 1) targeting B7H3, a CD8 alpha hinge region and transmembrane region, a 4-1BB costimulatory domain, a CD3 zeta signal domain and TLL1-scFv (SEQ ID NO: 6) targeting TLL1 from an N terminal to a C terminal. The TLL1-scFv can be efficiently combined with TLL1 protein, can inhibit a TGF-beta signal channel and block prostate cancer cell migration, and is integrated into CAR of targeted B7H3, so that the double-target CAR-T cell with direct killing and immune microenvironment regulation functions is successfully constructed. The CAR-T cell has a remarkable killing effect on a prostate cancer cell line DU145, can be strongly activated after being co-cultured with a target cell and secretes a large amount of IFN-gamma and TNF-alpha, and shows high immunocompetence. The invention provides a new synergistic immunotherapy strategy for the B7H3-positive prostate cancer with the TGF-beta signal channel activated.

The invention specifically discloses application of VGF as a diagnostic biomarker for prostatic cancer, and relates to the technical field of biological medicines. The secretory protein VGF is identified to be remarkably up-regulated in prostatic fluid of a prostatic cancer patient before puncture for the first time, high expression of the secretory protein VGF is proved to be independently related to shorter progression-free lifetime and total lifetime through a public database, and a brand-new liquid biopsy marker is provided for PCa non-invasive early screening and prognosis evaluation.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

Disclosed herein are methods including LATS kinase inhibitors or TIP60 inhibitors to perturb lineages within heterogenous tumors (e.g., prostate cancer) and enhance responsiveness to Androgen Receptor Signaling Inhibitor (ARSI) therapy or other therapeutic agents that target adenocarcinoma lineages (e.g., PSMA or STEAP1-expressing tumor cells.

The present disclosure provides methods for treating prostate cancer patients with an anti-STEAP1 antigen-binding protein such as xaluritamig either as monotherapy or in combination with another therapeutic agent.

Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator (SGRM) are disclosed. The AR antagonist may be enzalutamide. The SGRM may be an octahydro fused azadecalin compound, such as exicorilant, ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone which has the structure: The AR antagonist and the SGRM may be administered once per day, and may be administered with food. Enzalutamide doses may be 150-200 mg / day, e.g., 160 mg / day. Exicorilant doses may be 100-350 mg / day, e.g., 240 mg / day, or 280 mg / day, or 320 mg / day.

The present invention relates to a solid dispersion comprising enzalutamide or its pharmaceutically acceptable salts, hydroxypropyl methylcellulose phthalate (HPMCP), soluplus® (polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol), surfactant, and optionally at least one pharmaceutically acceptable excipient. The present invention also relates to a pharmaceutical composition comprising the solid dispersion of enzalutamide and its use for treating prostate cancer. The present invention further relates to a process for preparation of the solid dispersion of enzalutamide and the pharmaceutical composition comprising the solid dispersion of enzalutamide.

Disclosed is an mIDH1 / NAMPT dual-target inhibitor, which is selected from a compound having a structure as shown in formula (I) or formula (II), or a pharmaceutically acceptable salt, racemate, stereoisomer, prodrug, or solvent compound thereof. The dual-target inhibitor of the present invention can effectively overcome the shortcomings of a single mIDH1 inhibitor and single NAMPT inhibitor having poor efficacy against solid tumors. Said inhibitor can inhibit the malignant proliferation of tumors, has a good therapeutic effect, has low toxicity, and can penetrate the blood-brain barrier, and it is not easy to acquire drug resistance to said inhibitor. Moreover, the inhibitor can be used to prepare a medicament for treating cancer or tumor-related diseases, the cancer or tumor-related diseases comprising multiple myeloma, leukemia, breast cancer, prostate cancer, lung cancer, liver cancer, gastric cancer, bone cancer, brain cancer, head and neck cancer, intestinal cancer, pancreatic cancer, bladder cancer, testicular cancer, ovarian cancer, and endometrial cancer.